Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The latest state to join the measles outbreak, which has been ongoing for quite some time now in the United States, is Kentucky. It has declared the outbreak, and has been confirmed by the US Centers for Disease Control and Prevention (CDC) on Wednesday. So far, there has been a total of 1,267 confirmed cases of measles this year, nationwide.

For now, five active measles cases have been detected in Kentucky, and four of these are linked to the same outbreak.

"When there are measles outbreaks in other states and nearby countries, it is not surprising to see spread to Kentucky," Steven Stack, M.D., secretary of the Kentucky Cabinet for Health and Family Services, said in a statement. "Measles can be very serious, but it is avoidable through vaccination. We urge all parents to have their children vaccinated to ensure they are protected from preventable diseases like measles."

How Many Outbreaks And How Many Cases?

The CDC defines an outbreak as at least three related cases, and so far in 2025, 27 such outbreaks have been reported. Of them, 88% of the confirmed cases, which means 1,115 cases out of 1,267, are linked with the ongoing outbreak. In 2024, a total of 285 measles cases were reported by 33 jurisdictions, resulting in 16 outbreaks.

Since the late winter of 2024 till spring of 2025, Texas witnessed the country's largest outbreak, and three additional cases were reported this week. The case count in Texas now totals 753 since late January.

Last week, the New Mexico Department of Health reported five measles cases at the Luna County Detention Center in Deming. Officials are currently determining the vaccination status of people being held at the facility.

"The cases at Luna County Detention Center are a stark reminder that the measles outbreak in New Mexico is not over," Chad Smelser, M.D., a medical epidemiologist with the New Mexico Department of Health, said in a statement. "We urge everyone in New Mexico, especially Luna County residents, to ensure that they are fully vaccinated against measles."

So far, from the measles cases in Texas, New Mexico and Oklahoma, three deaths have been reported. Among them, two were elementary school-aged children from the West Texas epicenter, and one was an adult in New Mexico. All of them were unvaccinated.

What Vaccine Must One Take To Prevent Measles?

The CDC recommends two doses of the MMR vaccine as the "best way to protect against measles, mumps, and rubella". For children, it recommends two doses of MMRV.

The MMR vaccine is a combination of measles, mumps, and rubella vaccines, while the MMRV is a combination of measles, mumps, rubella, and varicella (chickenpox) vaccines.

In the US, two MMR vaccines are available for use, including M-M-R II, and PRIORIX. For MMRV, the vaccine is only licensed for children who are 12 months through 12 years of age. The first dose is usually administered between the ages of 12 to 15 months, while the second dose is administered between the ages of 4 to 6.

For older children, adolescents and adults, the two doses of MMR vaccines should be separated by at least 28 days.

What Is Measles?

CDC notes that it is a highly contagious virus, which means if one person has it, up to 9 out of 10 people nearby will also become infected. As per the Mayo Clinic, measles is caused by the measles virus, which can spread through an infected person's cough, sneeze, or even during conversations.

Signs And Symptoms

Measles symptoms appear 7 to 14 days after contact with the virus. Common measles symptoms include:

• High fever (may spike to more than 104° F)
• Cough
• Runny nose (coryza)
• Red, watery eyes (conjunctivitis)
• Rash

Netflix and adult film star Kylie Page's sudden death just at the age of 28 has come has a shock for the entertainment industry and her family. She was found dead at her apartment on June 25 after a friend called the cops when the friend was unable to reach her.

By the time the fire department arrived at her Hollywood residence, she had already been pronounced dead.

Kylie Page Death Reason

According to US Weekly's report the evidence suspect a drug overdose case as the police confirmed for finding fentanyl and drug paraphernalia. According to publicly available records from the Los Angeles County Medical Examiner, her cause of death is currently listed as “deferred,” indicating further investigation is underway, possibly involving suspected foul play. Her death was confirmed by the Canadian adult entertainment company she worked for.

Also Read: Kate Middleton Opens Up About Her 'Really Difficult' Time During Chemotherapy And How Nature Helped Her Heal

"The Brazzers team is deeply saddened to learn of Kylie Page’s passing,” the company said in a statement on X. “Kylie will be remembered for her laughter, kindness, and bringing light wherever she went. We extend our heartfelt condolences to Kylie’s family, friends, and fans during this difficult time.”

Fentanyl & Paraphernalia overdose: How These Drugs Impact Your Body?

Page's death has again reminded people of drug use and abuse in the entertainment industry cases like Matthew Perry's death and Liam Payne's death.

In case of Page, fentanyl and drug paraphernalia was found in her home.

As per the Edge Treatment Center that is licensed by the California State Department of Health Care Services, and US federal law, drug paraphernalia is any device, item, or component of any type which is mainly meant or crafted for the purpose of production, compounding, transforming, obscuring, generating, processing, prepping, injecting, inhaling, consuming, or otherwise including a banned drug into our bodies.

Common Drugs Linked with Paraphernalia

• Marijuana/cannabis
• Cocaine
• Heroin and other opioids
• Methamphetamines
• Ecstasy
• Inhalants

What Is Fentanyl and Why Is It So Dangerous?

As per the United States Drug Enforcement Administration (DEA), fentanyl is a potent synthetic opioid drug approved by the Food and Drug Administration for use as an analgesic (pain relief) and anesthetic. It is approximately 100 times more potent than morphine and 50 times more potent than heroin as an analgesic.

It is also known as Apace, China Girl, China Town, Dance Fever, and by other various names. It can be consumed through snorting, sniffing, smoking, or orally by pill or tablet. It could also be spiked onto blotter paper, patches or sold alone or in combination with heroin and other substances.

How Fentanyl Affects the Body and Mind

As per the National Institute on Drug Abuse, US, Fentanyl and other illegally produced synthetic opioids have played a major role in the overdose crisis in the United States since 2013.

Since about 2017, overdose deaths often involve use of multiple drugs. In many cases, fentanyl is one of these drugs. When fentanyl is mixed with other drugs, either on purpose or unknowingly, the combination can have more serious health effects.

Like other opioid pain relievers, fentanyl can cause a range of effects including relaxation, euphoria, pain relief, sedation, confusion, drowsiness, dizziness, nausea, vomiting, urinary retention, constricted pupils, and slowed breathing.

In cases of overdose, symptoms may include stupor, altered pupil size, cold and clammy skin, bluish discoloration (cyanosis), coma, and respiratory failure, which can be fatal. A combination of coma, pinpoint pupils, and respiratory depression is a strong indicator of opioid intoxication.

The U.S. Food and Drug Administration (FDA) has announced a significant update to the labeling of all extended-release medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). The change specifically targets the use of these drugs in children younger than six, warning about the risk of weight loss and other adverse reactions.

What Is ADHD?

ADHD is a common neurodevelopmental disorder that typically begins in childhood. It is characterized by symptoms such as inattention, hyperactivity, and impulsivity that can interfere with a child's development and daily functioning. Treatment usually involves a combination of behavioral therapy and medication, including stimulants like amphetamines and methylphenidate.

Labeling Change Reflects Off-Label Prescribing Trend

Although extended-release stimulants are not approved for use in children under six, the FDA notes that healthcare professionals sometimes prescribe them “off-label” to younger patients. This is typically done in cases where other treatments have failed or when symptoms are especially severe. However, the FDA warns that clinical trials have shown young children process these drugs differently from older children, often resulting in higher concentrations of the medication in the body.

These higher drug levels have been associated with an increased likelihood of side effects, including clinically significant weight loss. As a result, the FDA is requiring drug manufacturers to include a new “Limitation of Use” section in the prescribing information for all extended-release stimulant medications.

This section will outline the risks specific to children under six, including:

• Higher plasma concentrations of the drug
• Greater rates of side effects, including reduced appetite and weight loss
• The fact that extended-release formulations are not approved for this age group

Monitoring and Alternative Options Recommended

For young children already taking extended-release ADHD stimulants, the FDA advises healthcare providers to closely monitor the patient’s growth and development. Pediatricians should regularly chart weight and height to detect early signs of weight loss. If weight loss becomes a concern, alternative treatments should be considered.

These may include:

• Switching to immediate-release stimulants, which may be easier to manage in younger children
• Exploring non-medication interventions, such as behavioral therapies and parent training programs
• Reevaluating the overall treatment plan to ensure it aligns with the child’s developmental needs and physical health

What Should Parents and Caregivers Do?

Parents and caregivers are encouraged to stay alert for signs of weight loss in children taking extended-release stimulants. If any concerning changes in appetite or weight are noticed, it’s essential to consult the child’s pediatrician. The doctor can then weigh the benefits and potential harms of continuing the current medication and discuss safer alternatives if needed.

The FDA's move comes as part of its ongoing effort to improve pediatric medication safety and ensure that drug use in children is backed by evidence, especially when used outside of official guidelines.